Skip to main content

Table 3 Clinical results

From: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series

Case No. DTH Vac cycles Toxicity ELISPOT (CTL) CTL induction PFS (days) OS (days) Evaluation after 12 M
timing R1 R2 R1 R2
1 14 Before N/A N/A N/A N/A 554 967 PR
After N/A N/A
2 14 Before N/A N/A N/A N/A 562 1272 SD
After N/A N/A
3 14 Before + + + Still survive
After + 3+
4 + 14 Before N/A + + Still survive (962) CR
After 3+ 2+
  1. CTL cytotoxic T lymphocyte, DTH delayed type hypersensitivity, M month, N/A not available, OS overall survival, PD progressive disease, PFS progression-free survival, PR partial response, R vascular endothelial growth factor receptor, SD stable disease, Vac vaccination